| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Huang,Yi-Bin | Chairman | 1.60% | |
| Zhan,Hui-Ru | Director | 5.01% | |
| Bei,Nan-Mou | Director | 0.00% | |
| Huang,Hong-Ji | Director | 1.03% | |
| Xu,Guang-Yang | Independent Director | 0.02% | |
| Ge,Zhi-Gang | Independent Director | 0.00% | |
| Chen,Zhong-Cheng | Supervisor | 0.00% | |
| Huang,Yi-Sheng | Supervisor | 0.12% |
Change Person in Charge to Huang,Yi-Bin
2024/07/29
Change Company Name to FADE BIOTECHNOLOGY CO., LTD. (FORMER NAME: FADE BIOTECHNOLOGY CO., LTD.)
2023/04/27
Change Company Name to PharmaDax Inc.
2023/04/27
Change Company Name to FADE BIOTECHNOLOGY CO., LTD. (FORMER NAME: FADE BIOTECHNOLOGY CO., LTD.)
2022/10/26
Change Company Name to PharmaDax Inc.
2022/10/26
Change Company Name to FADE BIOTECHNOLOGY CO., LTD. (FORMER NAME: FADE BIOTECHNOLOGY CO., LTD.)
2022/07/11
Change Company Name to PharmaDax Inc.
2022/07/11
Change Capital to 2,000,000,000
2021/08/20
Change Person in Charge to Zhan,Hui-Ru
2018/08/01
Change Capital to 1,000,000,000
2012/09/21
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 306,376 | 906,332 | 303,910 |
| Operating cost | 108,166 | 220,370 | 130,970 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 198,210 | 685,962 | 172,940 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 198,210 | 685,962 | 172,940 |
| Operating expenses | 232,754 | 617,137 | 531,720 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -34,544 | 68,825 | -358,780 |
| Non-operating income and expenses | 29,920 | -23,692 | -79,891 |
| Net profit (loss) before tax | -4,624 | 45,133 | -438,671 |
| Income tax expense (benefits) | 0 | 25 | 30,029 |
| Net profit (loss) of ongoing business for the current period | -4,624 | 45,108 | -468,700 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -4,624 | 45,108 | -468,700 |
| Other comprehensive profit (loss), net | -60,360 | 23,547 | -13,394 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -64,984 | 68,655 | -482,094 |
| Net profit (loss) attributable to owners of parent company | -4,147 | 17,595 | -386,131 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | -477 | 27,513 | -82,569 |
| Comprehensive profit (loss) attributable to owners of parent company | -52,426 | 37,120 | -397,120 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | -12,558 | 31,535 | -84,974 |
| Basic earnings per share (yuan) | 0 | 0 | -5 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 53,607 | -76,127 | 9,155 |
| Net cash inflows (outflows) from investing activities | -19,310 | 7,781 | 108,885 |
| Net cash inflow (outflow) from financing activities | 78,028 | 182,801 | -232,991 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 21,692 | 5,178 | -9,544 |
| Increase (decrease) in cash and cash equivalents in the current period | 134,017 | 119,633 | -124,495 |
| Beginning balance of cash and cash equivalents | 238,303 | 118,670 | 243,165 |
| Ending balance of cash and cash equivalents | 372,320 | 238,303 | 118,670 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 764,595 | 504,773 | 479,986 |
| Non-current asset | 484,160 | 607,890 | 586,772 |
| Total asset | 1,248,755 | 1,112,663 | 1,066,758 |
| Current liability | 1,305,717 | 1,146,976 | 1,429,081 |
| Non-current liability | 352,666 | 356,831 | 275,601 |
| Total liability | 1,658,383 | 1,503,807 | 1,704,682 |
| share capital | 929,150 | 882,650 | 710,050 |
| Equity - secruity token | - | - | - |
| capital reserve | 2,805,854 | 2,805,854 | 2,821,002 |
| retained earning | -3,899,050 | -3,894,903 | -3,912,498 |
| Other equity | -12,743 | 35,536 | 16,011 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | -176,789 | -170,863 | -365,435 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | -232,839 | -220,281 | -272,489 |
| Total Equity | -409,628 | -391,144 | -637,924 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | -1 | -1 | -5 |
